Mizuho initiated coverage of Fortrea with a rating of Neutral and set a new price target of $27.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/25/2024 | $25.00 → $21.00 | Buy → Hold | Jefferies |
| 8/8/2024 | $31.00 → $27.00 | Outperform → In-line | Evercore ISI |
| 7/24/2024 | $30.00 | Equal Weight | Barclays |
| 6/6/2024 | $28.00 | Neutral | Goldman |
| 5/29/2024 | $27.00 | Hold | TD Cowen |
| 5/28/2024 | $27.00 | Neutral | Mizuho |
| 3/22/2024 | $43.00 | Neutral | Robert W. Baird |
| 3/6/2024 | $36.00 | Hold | Deutsche Bank |
4 - Fortrea Holdings Inc. (0001965040) (Issuer)
4 - Fortrea Holdings Inc. (0001965040) (Issuer)
SC 13G - Fortrea Holdings Inc. (0001965040) (Subject)
SC 13D/A - Fortrea Holdings Inc. (0001965040) (Subject)
SC 13D/A - Fortrea Holdings Inc. (0001965040) (Subject)
4 - Fortrea Holdings Inc. (0001965040) (Issuer)
3 - Fortrea Holdings Inc. (0001965040) (Issuer)
4 - Fortrea Holdings Inc. (0001965040) (Issuer)
Barclays analyst Luke Sergott reinstates Fortrea Holdings (NASDAQ:FTRE) with a Equal-Weight and announces $30 price target.
Across the recent three months, 8 analysts have shared their insights on Fortrea Holdings (NASDAQ:FTRE), expressing a variety of opinions spanning from bullish to bearish. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 2 4 2 0 Last 30D 0 0 0 1 0 1M Ago 0 0 0 0 0 2M Ago 0 0 4 0 0 3M Ago 0 2 0 1 0 Analysts have set 12-month price targets for Fortrea Holdings, revealing an average target of $28.75, a high estimate of $36.00, and a low estimate of $26.00. Highlighting a 21.87% decrease
B of A Securities analyst Derik De Bruin maintains Fortrea Holdings (NASDAQ:FTRE) with a Underperform and lowers the price target from $27 to $26.
For the three months ended September 30, 2024, from continuing operations: Revenues of $674.9 millionGAAP net loss of $(18.5) millionAdjusted EBITDA of $64.2 millionGAAP and adjusted net income (loss) per diluted share of $(0.21) and $0.23, respectivelyBook-to-bill ratio of 1.23x, resulting in 1.15x book-to-bill for the trailing 12 months DURHAM, N.C., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization ("CRO"), today reported financial results for the third quarter ended September 30, 2024. "We had a solid quarter of execution" said Tom Pike, chairman and CEO of Fortrea. "Our book-to-bill ratio for the quarter, as exp
DURHAM, N.C., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization ("CRO"), today announced that it will release its third quarter 2024 financial results before the market opens on Friday, November 8, 2024. Fortrea will host a conference call at 8:00 am ET that day to review its financial results and conduct a question-and-answer session. To participate in the earnings call, participants should register online at the Fortrea Investor Relations website. To avoid potential delays, please join at least 10 minutes prior to the start of the call. The conference call can also be accessed through the following earnings webcast l
For the three months ended June 30, 2024, from continuing operations: Revenues of $662.4 millionGAAP net loss of $(99.3) millionAdjusted EBITDA of $55.2 millionGAAP and adjusted diluted loss per share of $(1.11) and $(0.03), respectivelyBook-to-bill ratio of 0.96x, resulting in 1.16x book-to-bill for the trailing 12 monthsCompleted divestiture of assets relating to the Endpoint Clinical and Patient Access businessesDebt paydown of $504 million in the quarter using initial divestiture and securitization proceedsRevised full-year guidance DURHAM, N.C., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contr
Jefferies downgraded Fortrea from Buy to Hold and set a new price target of $21.00 from $25.00 previously
Evercore ISI downgraded Fortrea from Outperform to In-line and set a new price target of $27.00 from $31.00 previously
Barclays resumed coverage of Fortrea with a rating of Equal Weight and set a new price target of $30.00
DURHAM, N.C., July 11, 2024 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE), a leading global contract research organization (CRO), today announced that Robert "Bobby" Parks has been appointed as chief accounting officer (CAO), responsible for Fortrea's accounting function, including financial reporting, risk, controls and compliance in accordance with applicable standards, laws and regulations. "We are pleased to welcome Bobby to the Fortrea team, bringing his broad and deep experience from CROs and other fast-paced environments," said Fortrea Chief Financial Officer Jill McConnell. "Bobby has a track record of managing Sarbanes-Oxley Act requirements and internal controls, including for CROs,
DURHAM, N.C., May 16, 2024 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization ("CRO"), today announced the appointment of Machelle Sanders to the Company's Board of Directors. Ms. Sanders has served as North Carolina's Secretary of Commerce since February 2021 and brings strong domain expertise from more than 30 years of operational and quality assurance roles in pharmaceutical and biotechnology companies. "Machelle's impressive background in life sciences and public service enables her to bring a unique and welcome perspective to our Board," said Tom Pike, chairman and CEO. "She is a highly respected leader, who understands our cu
DURHAM, N.C., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today announced it convened last week the inaugural meeting of its Site Advisory Board, a collaboration between clinical research investigator sites ("sites") and industry leaders to create a better clinical trial experience for sites, patients and clinical study sponsors ("sponsors") by targeting changes in technology, operational planning and delivery, commercial terms and community engagement. Fortrea places sites and investigators at the forefront of clinical trial planning, leveraging their perspectives to drive changes that will improve the sp
For the three months ended September 30, 2024, from continuing operations: Revenues of $674.9 millionGAAP net loss of $(18.5) millionAdjusted EBITDA of $64.2 millionGAAP and adjusted net income (loss) per diluted share of $(0.21) and $0.23, respectivelyBook-to-bill ratio of 1.23x, resulting in 1.15x book-to-bill for the trailing 12 months DURHAM, N.C., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization ("CRO"), today reported financial results for the third quarter ended September 30, 2024. "We had a solid quarter of execution" said Tom Pike, chairman and CEO of Fortrea. "Our book-to-bill ratio for the quarter, as exp
DURHAM, N.C., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization ("CRO"), today announced that it will release its third quarter 2024 financial results before the market opens on Friday, November 8, 2024. Fortrea will host a conference call at 8:00 am ET that day to review its financial results and conduct a question-and-answer session. To participate in the earnings call, participants should register online at the Fortrea Investor Relations website. To avoid potential delays, please join at least 10 minutes prior to the start of the call. The conference call can also be accessed through the following earnings webcast l
For the three months ended June 30, 2024, from continuing operations: Revenues of $662.4 millionGAAP net loss of $(99.3) millionAdjusted EBITDA of $55.2 millionGAAP and adjusted diluted loss per share of $(1.11) and $(0.03), respectivelyBook-to-bill ratio of 0.96x, resulting in 1.16x book-to-bill for the trailing 12 monthsCompleted divestiture of assets relating to the Endpoint Clinical and Patient Access businessesDebt paydown of $504 million in the quarter using initial divestiture and securitization proceedsRevised full-year guidance DURHAM, N.C., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contr
SCHEDULE 13G - Fortrea Holdings Inc. (0001965040) (Subject)
10-Q - Fortrea Holdings Inc. (0001965040) (Filer)
8-K - Fortrea Holdings Inc. (0001965040) (Filer)